Hussman Strategic Advisors Inc. Invests $2.69 Million in Humana Inc. $HUM

Key Points

• Hussman Strategic Advisors opened a new position in Humana, purchasing 10,500 shares in Q4 valued at about $2.689 million.
• Humana topped Q1 estimates with $10.31 EPS (vs. $9.97 expected) and $39.65 billion in revenue (up 23.5% YoY), and set FY 2026 guidance at roughly 9.00 EPS (analysts forecast ~9.06).
• Analyst reaction is mixed: several firms have sharply raised price targets, yet the consensus rating remains Hold with an average price target of $247.61.

Hussman Strategic Advisors Inc. acquired a new position in shares of Humana Inc. (NYSE:HUM - Free Report) in the 4th quarter, according to its most recent disclosure with the SEC. The fund acquired 10,500 shares of the insurance provider's stock, valued at approximately $2,689,000.

Several other institutional investors have also modified their holdings of HUM. CoreCap Advisors LLC lifted its position in shares of Humana by 54.4% during the 4th quarter. CoreCap Advisors LLC now owns 105 shares of the insurance provider's stock worth $27,000 after purchasing an additional 37 shares during the last quarter. Rosenberg Matthew Hamilton lifted its position in shares of Humana by 136.0% during the 4th quarter. Rosenberg Matthew Hamilton now owns 118 shares of the insurance provider's stock worth $30,000 after purchasing an additional 68 shares during the last quarter. Mather Group LLC. purchased a new stake in shares of Humana during the 3rd quarter worth $34,000. Larson Financial Group LLC lifted its position in shares of Humana by 114.1% during the 3rd quarter. Larson Financial Group LLC now owns 152 shares of the insurance provider's stock worth $40,000 after purchasing an additional 81 shares during the last quarter. Finally, Fulcrum Asset Management LLP purchased a new stake in shares of Humana during the 3rd quarter worth $42,000. 92.38% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, insider Sanjay K. Shetty purchased 810 shares of the company's stock in a transaction dated Monday, February 23rd. The shares were acquired at an average cost of $185.21 per share, for a total transaction of $150,020.10. Following the completion of the purchase, the insider directly owned 11,657 shares in the company, valued at $2,158,992.97. The trade was a 7.47% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.20% of the stock is currently owned by company insiders.

Humana Trading Down 1.1%

Shares of Humana stock opened at $233.87 on Friday. Humana Inc. has a 52-week low of $163.11 and a 52-week high of $315.35. The company has a quick ratio of 2.00, a current ratio of 1.77 and a debt-to-equity ratio of 0.66. The company's 50-day simple moving average is $188.41 and its 200-day simple moving average is $227.22. The firm has a market cap of $28.08 billion, a price-to-earnings ratio of 25.01, a price-to-earnings-growth ratio of 2.50 and a beta of 0.67.

Humana (NYSE:HUM - Get Free Report) last issued its quarterly earnings results on Wednesday, April 29th. The insurance provider reported $10.31 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $9.97 by $0.34. Humana had a net margin of 0.82% and a return on equity of 10.45%. The business had revenue of $39.65 billion for the quarter, compared to analyst estimates of $39.37 billion. During the same period in the previous year, the business posted $11.58 earnings per share. The business's revenue was up 23.5% compared to the same quarter last year. Humana has set its FY 2026 guidance at 9.000- EPS. As a group, equities research analysts anticipate that Humana Inc. will post 9.06 earnings per share for the current year.

Humana Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Friday, June 26th will be paid a dividend of $0.885 per share. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.5%. The ex-dividend date is Friday, June 26th. Humana's payout ratio is 37.86%.

Trending Headlines about Humana

Here are the key news stories impacting Humana this week:

• Positive Sentiment: Multiple brokers lifted price targets sharply (Jefferies, Mizuho, Cantor, Evercore, Truist, Leerink, Deutsche Bank), signaling renewed upside expectations and analyst confidence after the quarter. Jefferies PT to $290 Mizuho PT to $290 Cantor PT to $264
• Positive Sentiment: Company aims for at least a 3% Medicare Advantage margin by 2028 while preparing 2027 bids and integrating MaxHealth — a clear operational target that can support future margin recovery. MA margin target article
• Positive Sentiment: Deutsche Bank and other shops issued constructive commentary/forecasts supporting the stock after Q1, reinforcing buy-side interest. Deutsche Bank positive forecast
• Neutral Sentiment: Sector context: Humana was one of the top performers in April (≈+36%), nearly neck-and-neck with UnitedHealth; market rotation and sector momentum are lifting valuation comparisons. April returns piece
• Neutral Sentiment: Analyst consensus remains around "Hold"/"Market Perform" despite PT changes, so expectations are mixed rather than uniformly bullish. Consensus Hold report
• Negative Sentiment: Goldman raised its target to $195 but kept a sell rating — signaling conviction that the current price is rich versus fundamentals and creating downside pressure. Goldman sell rating
• Negative Sentiment: JPMorgan raised its target to $214 but kept a neutral rating — the PT implies downside from current levels and highlights lingering skepticism about sustainability of margins. JPMorgan PT to $214
• Negative Sentiment: Despite beating Q1 estimates, Humana warned Medicare payments may not keep pace with costs and reported a decline in Medicare Advantage Star ratings; those operational/framing issues are cited by multiple outlets as reasons the stock is under pressure. Q1 beat but Star ratings concern Bloomberg Law

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the stock. Truist Financial lifted their price objective on shares of Humana from $220.00 to $270.00 and gave the stock a "hold" rating in a research report on Thursday. Mizuho boosted their price target on shares of Humana from $258.00 to $290.00 in a research report on Thursday. UBS Group boosted their price target on shares of Humana from $195.00 to $262.00 and gave the company a "neutral" rating in a research report on Thursday. Cantor Fitzgerald boosted their price target on shares of Humana from $201.00 to $264.00 in a research report on Thursday. Finally, Deutsche Bank Aktiengesellschaft boosted their price target on shares of Humana from $180.00 to $235.00 and gave the company a "hold" rating in a research report on Thursday. Seven analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and four have issued a Sell rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Hold" and a consensus price target of $247.61.

About Humana

Humana Inc NYSE: HUM is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana's products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.

In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.

Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc. (NYSE:HUM - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.